Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 922
- Registration Number
- NCT01031680
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
- Conditions
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01002807
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
Dapagliflozin DPPIV Inhibitor add-on Study
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 833
- Registration Number
- NCT00984867
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 154
- Registration Number
- NCT00976495
- Locations
- 🇺🇸
Prism Research, St. Paul, Minnesota, United States
🇺🇸Memorial Hospital Of Rhode Island, Pawtucket, Rhode Island, United States
🇳🇱Local Institution, Groningen, Netherlands
Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus Patients
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 417
- Registration Number
- NCT00972244
- Locations
- 🇯🇵
Research Site, Yamato, Japan
Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT00930865
- Locations
- 🇺🇸
Ppd Development, Lp, Austin, Texas, United States
Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT00908271
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00904176
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1093
- Registration Number
- NCT00859898
- Locations
- 🇺🇸
Clinical Research Advantage, Inc., Tempe, Arizona, United States
🇺🇸Southland Clinical Research Center, Inc., Fountain Valley, California, United States
🇺🇸Nextphase Clinical Trials, Inc., Miami, Florida, United States
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2013-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 182
- Registration Number
- NCT00855166
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.